A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
Latest Information Update: 21 May 2025
At a glance
- Drugs Lutikizumab (Primary) ; Ravagalimab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 21 May 2025 New trial record